The Lost Malaria MS Link: Over 140 Years of Forgotten Research That Changes Everything

What if the answer to MS has been hiding in plain sight since 1880?

Every day, people with multiple sclerosis are told there’s no known cause for their disease. They’re told their immune system is attacking their nerves for unknown reasons, and the best that standard of care can offer is immune-suppressing drugs that do not stop the progression.

But what if that’s not the whole story?

What if there’s over 100 years of peer-reviewed research—published in prestigious medical journals—showing that MS is linked to parasitic infections? Research that documented successful treatments. Research that showed patients recovering from MS.

This research exists, yet was mysteriously abandoned.

This post reveals the research timeline that mainstream medicine has forgotten—research that could change everything about how we understand and treat MS.

The Breakthrough Study That Validates 100 Years of Research

Let’s start with something recent that should have made headlines everywhere:

The 2021 University of Calgary Study

In September 2021, researchers at the University of Calgary—who are leaders in publishing important studies about the microbiome and MS—published groundbreaking research in a major medical journal.

They gave 35 primary progressive MS (PPMS) patients hydroxychloroquine—an antimalarial drug—for 18 months.

What was expected: Normally, at least 40% of participants (14 out of 35 people) should have experienced a decline in their ability to walk over those 18 months.

What actually happened: Only 8 got worse.

The antimalarial drug hydroxychloroquine significantly reduced disability progression in these PPMS patients—more effectively than any MS disease-modifying drug on the market.

The researchers found that hydroxychloroquine reduced the activity of immune cells in the central nervous system and had neuroprotective effects.

Their conclusion: “HCQ treatment was associated with reduced disability worsening. HCQ is a promising treatment candidate for PPMS and should be investigated further in randomized controlled clinical trials.”

The question we must ask: If a malaria drug helps MS patients, what does that tell us about what’s actually causing MS?

This isn’t new information. This is validation of research that’s been documented since the 1880s.

The Kissler Studies: The Comprehensive 100-Year Review

In 2001, researcher H. Kissler published a landmark scientific journal article titled, “Is multiple sclerosis caused by a silent infection with malarial parasites? A historico-epidemiological approach.”

Kissler reviewed observations from many researchers spanning more than 100 years and made a striking discovery.

The Only Parasite with Matching Distribution

He compared distribution studies of MS with those of other diseases and found that the only parasite with similar distribution to MS was plasmodium—the parasite that causes malaria.

The Antibody Evidence

Kissler shared research that found:

• Antibodies against malaria parasites in 30-40% of MS patients
• Actual malaria parasites in about 20% of MS patients

This is extremely significant because it’s a well-known fact that finding malaria parasites in bloodwork is extremely difficult. Yet antibodies against malaria in MS participants were mostly discovered on the first try.

No antibodies against malaria were found in patients suffering from other diseases.

A separate study of healthy people, blood donors, and accident victims showed zero antibodies against malaria strains.

The Stunning Detail

None of the MS patients had ever visited a tropical region that had malaria. They had no history of traveling to malaria-endemic areas.

Yet their bodies showed clear evidence of malarial infection.

Historical Textbook Evidence

Kissler referenced medical textbooks that described chronic malaria in ways that sound exactly like MS:

1936 textbook: Cases of chronic malaria characterized mainly by neurological symptoms which often resembled MS, but typical malarial fever was not present and the parasites were very difficult to detect.

1963 textbook: Common neurological symptoms of malarial infections included:

• Slow speech (scanning speech)
• Tremors (intention tremor)
• Spastic gait
• Muscle twitches
• Involuntary eye movements (nystagmus)
• Reduced vision and depth perception affecting balance and coordination.

These are classic MS symptoms.

Early Clinical Observations

In 1889, neurologist Prince reported on six cases where malaria was followed by MS. He later found three more cases. Most of his patients had contracted malaria while serving as soldiers in the southern USA during the Civil War.

The Geographic Evidence

Kissler reviewed findings from researchers who compared worldwide maps of malaria distribution to MS distribution.

The pattern was undeniable:

• Where malaria was endemic, there was no MS
• There was a gradual decrease in MS and increase in malaria moving from north to south in the northern hemisphere
• The same was true vice versa for the southern hemisphere

One researcher suspected that one disease was extinguishing the other.

In the United States: Where malaria was endemic between 1929 and 1938, there were later fewer cases of MS.

And critically: MS patients treated for malaria had significant improvements.

Why Has This Been Forgotten?

Because chronic silent malaria is uncommon and overlooked, it has been almost forgotten in current textbooks. The term “malaria” is not mentioned in MS textbooks, so neurologists don’t consider malaria when diagnosing MS.

The Quinine Studies: Treatment Success from 1892 to 1935

Now consider the documented treatment evidence spanning over 40 years.

1892: The First Treatment Cases

Two researchers wrote a paper about three situations where MS and malaria occurred together:

1. Temporary symptoms, only present during malarial fever
2. Symptoms appeared after fever with varying duration
3. Symptoms appeared suddenly without malarial fever.

These authors found that the malarial drug quinine was helpful in the 2 cases of MS that they treated.

1897: Spiller’s Observation

Spiller reported a case of malaria showing symptoms of disseminated sclerosis similar to MS, mostly affecting one side of the body. He recognized how remarkably similar this malaria case was to MS.

1899: Mannaberg’s Revolutionary Theory

Mannaberg was likely the first to suggest that MS could be caused by an infection of malarial parasites. He believed that symptoms resembling MS played a major role in malaria.

1900: The Autopsy That Proved It

Spiller published a fascinating case study of a patient who suffered eight years with MS, had no history of malaria, and had never shown any malarial attacks.

The malaria diagnosis was discovered only after his death when malaria parasites were seen moving out of small blood vessels throughout the brain and spinal cord.

This patient had MS symptoms for eight years—and the malaria parasites were there the entire time, undetected.

1904: Müller’s Recommendation

Müller thought MS and malaria were caused by blockages of small blood vessels in the brain by parasitized red blood cells. He recommended quinine as a useful remedy in all cases of MS, especially when vertigo was a major symptom.

1917: Castellani’s CURED Cases

Dr. Castellani documented something remarkable:

“I have seen one case in the Balkans, and three in the Tropics, of a malarial condition closely simulating disseminated sclerosis, with scanning speech, intentional tremor, nystagmus, spastic gait, and increased reflexes. All the cases were cured by quinine.“

All four cases were completely CURED by the antimalarial drug quinine.

But here’s the tragedy: Dr. Castellani concluded that because these cases responded well to quinine, they couldn’t have been “real, genuine MS.”

The circular logic that cost us a century:

• If it responds to treatment, it can’t be MS
• If it’s MS, it can’t be treatable.

1917: Craig’s Diagnostic Method

Craig concluded from the feverish reaction he observed in an MS patient after administering quinine—without even seeing a single parasite—that the patient most likely had malaria.

He wrote: “The enlarged spleen, the history of typical malarial attacks and the characteristic reaction of chronic malaria to quinine were sufficient evidence, without the presence of plasmodia, to attribute lesions in the patient’s central nervous system to malarial infections.”

1921: The Quinine Testing Method

Mühlens stated that injection of small doses of quinine had become a well-known method to detect malaria, as it showed parasites for the first time after administration of quinine.

1920s: Marburg’s Success

Marburg treated MS patients with quinine and found that this drug improved the health and well-being of MS patients, as long as it was given in small doses.

1930-1935: Brickner’s Five-Year Study

Between 1930 and 1935, Dr. Brickner in New York systematically investigated how useful quinine was in treating MS.

He treated 49 patients over 5 years.

His conclusion: “The experience of five years with forty-nine patients seems to justify the conclusion that quinine is beneficial in cases of multiple sclerosis, particularly in the early stages.”

He clearly stated: “A general view of the present status of the forty-nine patients as individuals strongly indicates that quinine therapy has been helpful.”

The Herxheimer Reaction Discovery

Brickner found that in some cases of treating MS with quinine, there was a slight increase in symptoms followed by marked improvement. He believed the initial downturn was a good sign that the drug would be helpful.

This is now known as a Herxheimer reaction—a sudden increase in symptom intensity that usually occurs within 72 hours after introducing treatment. It’s a classic sign that a treatment is killing off parasites.

1945: Perret-Gentil’s Method

In Switzerland, Perret-Gentil recommended looking for parasites at the moment when treatment with quinine begins, because it was then that he was able to observe bouts of fever together with the presence of malarial parasites.

Why Was Brickner’s Research Abandoned?

Brickner theorized that MS lesions might be caused by a circulating fatty substance neutralized by quinine. This theory was proven wrong, and the idea that quinine could treat MS was not accepted.

His findings were completely forgotten.

In 1965, when Sibley published an overview of drug treatments for MS, he didn’t even mention Brickner’s studies.

The critical point: Because Brickner’s claim that quinine helps MS has never been disproven, it remains unchallenged scientific evidence.

The Remarkable 1934 Case Study: Complete Recovery Documented

The following documented case study shows just how effective quinine treatment can be.

Multiple Sclerosis Treatment with Quinine Hydrochloride by Dr. Stanley D. Conklin, MD

Patient Profile – October 30, 1934:

• 27-year-old married American housewife
• No symptoms until three weeks before hospital admission
• Symptoms: tingling in hands, difficulty writing, clumsy hands
• Symptoms rapidly worsened:
  • Could not walk without support
  • Difficulty rising from sitting position
  • Personality changes, memory affected
  • Severe abdominal pain
  • Nystagmus (uncontrolled eye movement)
  • Severe uncoordination—would fall when walking
• Diagnosis: Multiple Sclerosis

Treatment Protocol:

Neurologist WG Spiller of Philadelphia recommended quinine hydrochloride following Dr. Brickner’s protocol.

• Start date: November 18, 1934
• Dosage: 5 grains of quinine hydrochloride three times per day (15 grains total daily)

The Remarkable Recovery Timeline:

By end of second week: Already improved! Pains in hands less frequent and shorter duration. Sleep improved. Able to sit in wheelchair. Appetite improved.

By end of third week: All neurological symptoms subsiding. Pain in hands only twice per day. Able to walk alone a little each day. Slept well without medication.

February 15, 1935 (3 months later): Walking almost normally. Pain and tingling in hands practically gone. No difficulty writing or feeding herself. Memory perfect. Good appetite, gaining weight.

September 13, 1935 (10 months later): Excellent condition! Led normal life all summer—long walks, bicycling, swimming without symptoms. Tremor in hands and feet not noticed since early spring.

January 10, 1936: Condition very good. Dosage reduced to 5 grains once daily.

January 30, 1937: Patient wrote that she felt perfectly well during 1936 except for having flu once.

February 2, 1937: Dr. Brickner reported she was symptom-free and still taking quinine hydrochloride. Only remaining neurological sign was nystagmus. All other factors normal.

The Outcome

She took quinine continuously from November 1934 through at least February 1937—over two years—with immediate, continuous, and near complete relief from symptoms.

Some might question if this was spontaneous remission. But given the immediate improvement, continuous progress, and near complete symptom relief, the medical conclusion was clear: the therapy caused her recovery.

Her doctors believed that quinine hydrochloride therapy should be tried over a long period, no matter how long a patient has had MS or how dire their condition.

The Pathological Evidence: What’s Found in MS Brains

The physical evidence found in MS patients links directly to malaria infection.

Malaria Granulomas in MS

Granulomas are tiny clusters of white blood cells and other tissue that form as a reaction to infections.

In 1917, Durck found malaria granulomas in MS patients. He questioned whether MS was caused by malaria and thought that malaria granulomas could be the starting point of developing MS lesions.

Several other researchers also found granulomas, though their findings were not further studied.

Capillary Hemorrhages: The Smoking Gun

A capillary hemorrhage occurs when a very small blood vessel or capillary breaks open. MS lesions are always located around small veins.

The timeline:

• 1849: Frerichs found several hemorrhages in a case of MS
• 1911: Two researchers were convinced MS was caused by an infectious agent and that lesion formation was the result of capillary hemorrhages
• 1916: Dawson found small capillary hemorrhages in MS
• 1917: Durck found hemorrhages in malarial brain infections, mostly in the same parts where MS lesions are usually located.
• 1942: Two neuropathologists wrote: “Whether the individual lesion [caused by malaria] is of the nature of a hemorrhage, a focus of necrosis [tissue death], or a granulomatous nodule, the end result is a patch of sclerosis. Multiple areas of sclerosis diffusely scattered would produce disturbance of cerebral function.”

They were describing MS pathology—caused by malaria.

Ring Hemorrhages and Iron Deposits

Red blood cells infected with malarial parasites cause circulatory disorders.

1988: Researchers found ring hemorrhages around obstructed small vessels in brain tissue commonly observed in cerebral malaria.

1982 and 1988: Different researchers found iron deposits surrounding lesions in ALL MS cases studied. They believed this ring was evidence of a past hemorrhage.

1943: Researchers observed deposits of iron directly surrounding MS lesions.

The connection: Small hemorrhages and demyelination are similar in both malaria and MS. Both cause a demyelinating disease in the brain.

Leptomeningitis: Identical in Both Conditions

Leptomeningitis is inflammation or infection of the thin membranes that cover the brain and spinal cord, called the leptomeninges.

A form of lymphocytic leptomeningitis is present in both MS and malaria.

1911: Two researchers described mild leptomeningitis in MS patients.

1917: Durck reported on leptomeningitis in cerebral malaria cases, finding mostly cells resembling lymphocytes with very few monocytes.

1958 and 1970: Researchers described chronic leptomeningitis in MS.

1975: Two researchers found inflammatory lesions in the meninges of the brain in 41% of their autopsied MS cases.

The pathological findings were the same between malaria and MS.

The Diagnostic Clue: Elevated Lactate Levels

Here’s a biomarker that ties everything together and can help with diagnosis.

What is Lactate?

Lactate (lactic acid) is a chemical produced when cells break down carbohydrates for energy.

Lactic acidosis occurs when lactic acid production exceeds clearance. This buildup can lead to neurological and psychiatric disorders such as major depressive disorder, schizophrenia, Alzheimer’s disease, and multiple sclerosis.

The Parasite Connection

Current medicine claims lactic acidosis is caused by toxins, lack of oxygen, and disease conditions. But it’s well understood in science that many parasites produce lactic acid.

Malarial parasites, schistosomes (blood flukes), and filarial worms are the parasites that produce the most measurable amounts of lactic acid from fermenting carbohydrates.

Why? Carbohydrates are the preferred food source for parasites. In most areas of the body, there’s minimal to no oxygen, so parasites must get energy almost solely by fermenting carbohydrates.

Schistosomes, worms, and most protozoa don’t need oxygen to survive.

The MS-Malaria Connection

Lactic acidosis is common in patients with both severe malaria AND MS.

Researchers believe that testing blood lactate levels may be a useful biomarker in MS.

The statistics:

• The amount of lactate in MS patients’ blood is linked to disability
• One study found lactate in MS patients was 2.8 times higher than in healthy controls.

Why Malaria Increases Lactate

Malarial parasites infecting red blood cells lead to:

1. Blood vessel obstruction and lack of oxygen in surrounding tissues
2. Increased anaerobic glycolysis (breakdown of glucose without oxygen)
3. The parasites themselves fermenting carbohydrates
4. Breakdown of glucose by activated immune cells
5. Anaerobic breakdown in oxygen-deprived cells due to parasite invasion and anemia
6. Impaired clearance of lactate by liver or kidneys due to organ damage.

Normal lactate levels: Less than 2 mmol/L
Hyperlactatemia: 2-4 mmol/L
Severe: 4 mmol/L or higher

Testing blood lactate could provide an important diagnostic clue for parasitic infection in MS patients.

Why Chronic Malaria Goes Undetected

Understanding why this infection is missed is crucial.

The Silent Infection Problem

The small number of annual reported malaria cases in developed countries indicates there’s likely a much larger number of undiagnosed cases, and furthermore, a huge number of “silent” cases not displaying typical malaria symptoms.

It’s a well-known fact that finding malaria parasites using current testing methods is extremely difficult.

The Immunity Theory

Researchers suspect that:

• A silent infection of malaria in early childhood provides immunity and protects against developing MS later in life
• A silent malarial infection during adolescence or adulthood can cause MS.

This explains the age distribution of MS onset.

How Protists Infect Us

Protists are single-celled parasites such as plasmodia, babesia, giardia, and amoebas. They cause diseases like:

• Malaria
• Trypanosomiasis (African sleeping sickness)
• Leishmaniasis
• Toxoplasmosis
• Amoebic dysentery

Babesia has been specifically linked to multiple sclerosis.

Many protists are spread through biting insects—mosquitoes, ticks, and biting flies.

Protist infections are often misdiagnosed.

The mechanism: Malaria and Babesia protists infect red blood cells so they can’t move freely in blood vessels and end up sticking to blood vessel walls. In time, infected RBCs enter the central nervous system, causing cerebral malaria.

Dr. Fry’s Groundbreaking Discovery

Dr. Fry, founder of Fry Laboratories, discovered a new type of protist in MS patients.

At first, he thought it was Babesia, but after extensive research he discovered it was actually “a malaria-like organism that forms biofilm communities in the blood and has an extremely complex lifecycle. It is a blood-loving parasite.”

After mapping the genome, he discovered it’s a new type of protist similar to malaria and Babesia but more complex genetically—similar to both a parasitic worm and a protozoan.

This discovery helps explain why the infection is so difficult to detect and treat.

Malaria Symptoms Mirror MS Symptoms Exactly

Let’s look at the remarkable overlap.

Common Malaria Symptoms

• Fever, chills, sweats
• Headaches
• Nausea and vomiting
• Body aches
• Feeling unwell.

Clinical Findings

• Elevated temperatures
• Perspiration
• Weakness
• Enlarged spleen and liver
• Anemia
• Decreased platelets (thrombocytopenia)
• Parasites in blood (when detectable).

Severe Malaria in the Central Nervous System

The neurological symptoms of cerebral malaria are identical to MS:

• Paralysis affecting one side of the body
• Cranial nerve palsies – partial weakness or full paralysis
• Myelitis-like syndrome – pain, weakness, loss of bladder control, abnormal feeling in legs (burning, prickling, tingling)
• Psychosis – amnesia, lack of focus and concentration, insomnia, anxiety, depression, mania, confusion, delirium
• Ataxia – loss of muscle control, poor coordination/lack of balance, eye movement disorders, impaired speech
• Peripheral neuropathy
• Seizures
• Impaired consciousness and coma.

Additional Symptoms Common to Both

• Hearing loss and tinnitus
• Balance issues and dizziness
• Muscle aches, spasms, fatigue, pain, and weakness
• Vision problems including optic neuritis
• Blocked blood vessels and reduced blood flow in brain.

Which Body Parts Are Affected?

The brain, eye (retina, optic neuritis), gastrointestinal tract, bones, lungs, kidneys, and placenta can all be affected during and even long after a malarial infection.

Post-Malaria Neurological Syndrome

This explains MS relapses.

Neurological or psychiatric symptoms can appear after a symptom-free period of two months following a supposedly cured malarial infection with negative blood test and no alternative diagnosis.

This pattern matches the relapsing-remitting nature of MS perfectly.

Why This Critical Research Was Abandoned

Here’s the uncomfortable truth about the shift that buried this research.

The McDonald Criteria Shift of 2001

The first McDonald Criteria for MS diagnosis was introduced in 2001. This marked a fundamental shift in MS research.

Before 2001:
Research focused on identifying infectious agents that cause MS in hopes of finding a cure.

After 2001:
Research shifted to development of disease-modifying maintenance pharmaceuticals that suppress immune function in an attempt to manage disease.

The Consequences

Although the criteria has been revised in 2005, 2010, and 2017, not much has changed with respect to diagnosis and treatment of MS.

This shift has resulted in:

• Abandonment of infectious disease research
• Lack of investigation into potential cures
• A very lucrative medical and pharmaceutical complex
• Continued suffering, disability, and premature death in patients.

The Pattern Over Time

MS was a rare neurological disorder in the mid-19th century.

Today it’s the most common disabling neurological disease in young adults.

The shift from finding cures to managing symptoms has been devastating for patients—but highly profitable for pharmaceutical companies.

Over 100 years of research showing successful treatment with antimalarial drugs was set aside in favor of patentable immune-suppressing medications that don’t address the root cause.

Current Treatment Options and Considerations

Based on historical and modern research, here are treatment approaches that have shown effectiveness.

Historical Success: Quinine

In the late 1800s to early 1900s, physicians treated MS patients with quinine and quinine hydrochloride with documented success:

• Significant symptom improvements
• Complete recoveries in multiple cases
• Long-term remission when treatment continued.

Modern CDC Recommendation

Currently, the American CDC recommends treating malaria with artesunate, which is the injectable form of artemisinin wormwood.

Combination Approaches

Other studies report that combining artesunate with pearl garlic oil improved treatment efficacy in animal studies.

Triple artemisinin-based combinations (TACTs) may help protect against the risk of malarial parasites developing drug resistance. This involves combining two different slowly eliminated antimalarial drugs with artesunate.

Supportive Therapies

Oxygen therapies can help improve recovery from malaria by addressing the tissue hypoxia caused by parasitized red blood cells blocking circulation.

The 2021 Study Protocol

The University of Calgary study used:

• Hydroxychloroquine 200mg twice daily for 18 months
• This is a typical dose used to treat lupus and rheumatoid arthritis.

Important considerations:

• HCQ can damage the retina—regular eye exams are essential
• This dose won’t cure MS but may slow progression
• More comprehensive treatment addressing multiple parasites is needed for full recovery.

Expect Herxheimer Reactions

As Brickner observed in the 1920s-1930s, there’s often a slight worsening of symptoms at the beginning of treatment, followed by significant improvement.

A Herxheimer reaction is a sudden increase in symptom intensity (not necessarily with fever) that usually occurs within 72 hours after introducing treatment. This is actually a positive sign that the treatment is killing parasites.

Working With Practitioners

Treatment of chronic parasitic infections requires:

• Comprehensive testing beyond standard tests
• Holistic approach addressing gut health and immune support
• Proper dosing and duration (historical cases used treatment for 2+ years)
• Monitoring for both improvement and Herxheimer reactions
• Treatment of multiple co-infections.

Diagnostic Approach for Chronic Silent Malaria in MS

Because chronic silent malaria is very difficult to detect in patients, here are diagnostic criteria to help:

Blood Work Indicators

In chronic silent cases:

• Parasites are hard to find
• Antibodies may not be evident.

However, look for:

• Elevated lactate levels (2.8x higher in MS patients)
• RBCs infected by parasites → elevated MCV, MCH, MCHC
• Anemia (common in both malaria and MS)
• Activation and increase in B and T immune cells
• Eventual T cell exhaustion
• Low vitamin D levels (common in both conditions)
• Mild decrease in blood platelets (thrombocytopenia)
• Elevated bilirubin
• Elevated aminotransferases (liver enzymes).

Testing Options

• Blood smear test (may or may not show parasites)
• Malaria rapid diagnostic test (RDT)
• PCR test
• Antibody blood test using indirect immunofluorescence (IFA) or ELISA (may detect past exposure).

Clinical Signs

• Enlarged spleen
• History of symptoms matching malarial infection
• Response to quinine or antimalarial drugs (diagnostic and therapeutic)
• Neurological symptoms matching cerebral malaria
• Geographic history (even if not tropical—silent infections occur in temperate zones).

The Quinine Diagnostic Test

As documented since 1921, administering small doses of quinine can trigger the appearance of parasites or fever, confirming the diagnosis. This was a well-known diagnostic method for detecting hidden malarial infections.

The Live Disease Free Academy

When students treat parasites and other infections effectively, they experience:

• Fewer urgent bathroom trips within 1-2 weeks
• Less pain, fatigue, stiffness, and spasticity
• More energy and mental clarity
• Greater strength
• Significant symptom improvements
• Many achieve full recovery.

This wouldn’t be possible if MS were truly autoimmune.

If MS were genuinely a disease where the immune system mistakenly attacks healthy tissue, treating infections wouldn’t work.

But it does work. Consistently. Repeatedly. For thousands of people.

The Pattern We See in MS Patients

Most people diagnosed with MS have:

• A history of antibiotic use (sometimes before age 10) that devastated their gut microbiome
• Vulnerability to environmental parasites
• A diet high in processed carbohydrates that fed disease-causing organisms
• Multiple parasitic infections by the time of diagnosis
• Severe dysbiosis (imbalance of microbes in the body).

When we address the dysbiosis and treat the parasites comprehensively, the disease process stops.

Patients go into remission. They experience life-changing symptom improvements. Many fully recover.

The Evidence Summary: What We Know

Let’s consolidate over 100 years of research:

✓ 75 scientific papers dating back to the 1880s documenting malaria organisms in MS patients

✓ Antibodies found in 30-40% of MS patients tested

✓ Parasites found in 20% of MS patients tested

✓ No antibodies found in patients with other diseases or healthy controls

✓ None of the MS patients had ever visited tropical malaria regions

✓ Geographic distribution of MS matches malaria patterns better than any other disease

✓ Successful treatment with antimalarial drugs documented from 1892-1935

✓ Complete recovery documented in multiple case studies with quinine

✓ Pathological evidence of malaria granulomas, capillary hemorrhages, ring hemorrhages, iron deposits, and leptomeningitis in MS patients

✓ Elevated lactate biomarker in MS patients (2.8x higher) indicating parasitic fermentation

✓ Identical symptoms between cerebral malaria and MS

✓ Post-malaria neurological syndrome explaining MS relapses

✓ 2021 study validating antimalarial treatment significantly slows MS progression

✓ New malaria-like protist discovered in MS patients by Dr. Fry

✓ Documented Herxheimer reactions when treating MS patients with antimalarials

✓ Clinical observations by multiple physicians over 40+ years showing benefit.

What Needs to Change

For the Medical System

Recognition: MS needs to be recognized as an infectious disease caused by a parasitic infestation, particularly malaria and malaria-like protists.

Testing: Standard protocols must include testing for parasitic infections, not just ruling out other conditions before defaulting to “autoimmune.”

Treatment: Approaches must address root causes—treating infections—rather than only suppressing immune function.

Research: Funding must be directed toward investigating antimalarial and antiparasitic treatments, not just developing new immune-suppressing drugs.

Education: Neurologists need training in parasitology and infectious disease, especially chronic silent infections.

For Patients

Understanding: The immune system is not broken—it is fighting chronic infections. The immune response is appropriate; there’s just collateral damage to myelin.

Hope: Recovery IS possible when you address the root cause.

Approach: Treatment must be comprehensive and holistic, addressing multiple parasites and supporting the body’s natural healing.

Empowerment: You have the power to investigate and address the root cause. You don’t have to accept the theory that MS is “incurable.”

For Researchers

Validation: The 2021 Calgary study shows that antimalarials work. This deserves immediate follow-up with larger trials.

Investigation: Why was 100+ years of successful treatment abandoned? We need to examine this shift critically.

Innovation: Develop better testing for chronic silent malarial infections that evade standard detection.

Integration: Combine historical knowledge with modern science to develop comprehensive treatment protocols.

The Bottom Line

MS is not a mysterious autoimmune disease with an unknown cause.

The science shows compelling evidence that it is an infectious disease caused by parasitic infestation, particularly involving malaria and malaria-like parasites.

The research has been there all along—dating back to the 1880s. It was documented, peer-reviewed, published in prestigious medical journals, showed successful treatments and impressive recoveries, and then was mysteriously abandoned in favor of the autoimmune theory.

But you don’t have to accept that narrative anymore.

The evidence is overwhelming. The geographic patterns match. The pathological findings are identical. The symptoms overlap completely. The treatments work. And real people are recovering.

When we treat infection, recovery happens.

There are real solutions to recover from parasites today!

To restore health, we must focus on treating the cause of inflammation, which are parasites. First, identify the enemy (parasites), then support the body and treat the parasites while following a holistic approach. When parasitic infections are treated effectively, we can overcome inflammation or disease.

If you’re frustrated with the fact that our standard of care STILL doesn’t offer a real solution for treating MS and other diseases, then click on the link below to watch Pam Bartha’s free masterclass training and discover REAL solutions that have allowed Pam and many others to live free from MS and other diseases.

CLICK Here to watch Pam’s masterclass training

 

Related Research Articles

For more information on this topic, explore these related posts:

• MS News: Malaria Drug May be a Promising Treatment for PPMS
• Multiple Sclerosis and Malarial Parasites Part 2
• Multiple Sclerosis and Malarial Parasites Part 3
• Protozoa Parasites in MS: MS is an Infectious Disease
• Parasites and Multiple Sclerosis: What’s The Connection?
• Multiple Sclerosis and the Parasite Babesia
• How Parasitic Worms Suppress the Immune System

For complete reference list, visit the malaria archives at LiveDiseaseFree.com/tag/malaria

 

References

Complete references available in the original research articles:

1. Kissler, H. (2001). Is multiple sclerosis caused by a silent infection with malarial parasites? A historico-epidemiological approach: Part I. Medical Hypotheses, 57(2), 180–187. https://pubmed.ncbi.nlm.nih.gov/11516218/ 
2. Kissler, H. (2001). Is multiple sclerosis caused by a silent infection with malarial parasites? A historico-epidemiological approach: Part II. Medical Hypotheses, 57(3), 292–301. https://pubmed.ncbi.nlm.nih.gov/11516219/ 
3. Metz LM, et al. (2021). Hydroxychloroquine for Primary Progressive Multiple Sclerosis. University of Calgary, AB, Canada. https://pubmed.ncbi.nlm.nih.gov/34590328/